| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514200500 | Lactoferrin | 14 |
| 20100279951 | METHOD OF TREATING ALLERGIC CONJUNCTIVITIS WITH CYCLOSPORIN COMPOSITIONS - Disclosed herein is a method of treating allergic conjunctivitis, the method comprising the step of topically administering to an eye affected with such a condition a composition comprising cyclosporin, at a concentration between about 0.001% (w/v) to about 0.01% (w/v). | 11-04-2010 |
| 20100286065 | TOPICAL METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES AND CONDITIONS - The present invention relates to a new therapeutic approach for the treatment of eye diseases or conditions that allows for the delivery of corticosteroids to the eye's surface but does not cause any of the usual side effects associated with topical administration of corticosteroids. More specifically, the present invention provides methods of treatment involving the administration of a corticosteroid prodrug, such as dexamethasone palmitate, to the surface of the eye. Also provided are pharmaceutical compositions and kits for carrying out such methods of treatment. | 11-11-2010 |
| 20100305045 | OMEGA-3 OIL CONTAINING OPHTHALMIC EMULSIONS - Disclosed herein are non-irritating ophthalmic emulsion compositions useful for treating ocular disorders including dry eye. More specifically, the ophthalmic compositions disclosed herein combine a high HLB surfactant and a low HLB surfactant together with an omega-3 fatty acid-containing oil having non-polar aliphatic side chains to form a therapeutic non-irritating eye drop. | 12-02-2010 |
| 20100305046 | STABLE CYCLOSPORINE CONTAINING OPHTHALMIC EMULSION FOR TREATING DRY EYES - Disclosed herein are stable oil-in-water emulsion ophthalmic topical liquid compositions having an average particle size less than 1 μm including at least one plant-derived oil other than castor oil wherein the oil comprises only aliphatic side chains free of polar pendent groups. The oil-in-water emulsion ophthalmic topical liquid compositions also include a hydrophilic surfactant having an HLB value between approximately 10 and 14, a vegetable oil-derived hydrophobic non-co-block surfactant having unsaturated side chains that contain less than four oxygen atoms having an HLB value between approximately 4 and 6 and is a liquid at room temperature. The oil-in-water emulsion ophthalmic topical liquid compositions disclosed herein can further include an amount of cyclosporine A effective to relieve dry eye symptoms. | 12-02-2010 |
| 20100305047 | CYCLOSPORIN DERIVATIVES FOR ENHANCING THE GROWTH OF HAIR - The present invention provides a method for the treatment of alopecia and/or enhancing hair growth in a patient, wherein said method comprises administering, preferably topically, to the skin, e.g. the scalp or the eyelid, a therapeutically effective amount of a cyclosporin A derivative selected from the group consisting of compounds represented by the formula: | 12-02-2010 |
| 20100317595 | COMPOSITIONS FOR ENHANCING NAIL GROWTH - The present invention is directed to compositions and methods for stimulating the growth of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to increase nail growth and thicken, strengthen and smooth the nail. The composition is also effective in strengthening and growing nails, including fingernails and toenails. | 12-16-2010 |
| 20100323972 | NON-IMMUNOSUPPRESSIVE CYCLOSPORIN FOR THE TREATMENT OF MUSCULAR DYSTROPHY - The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy. | 12-23-2010 |
| 20110009339 | METHOD OF TREATING BLURRED VISION AND OTHER CONDITIONS OF THE EYE WITH CYCLOSPORIN COMPOSITIONS - Disclosed herein is a method of treating blurred vision, of increasing keratocyte density, of increasing goblet cell density, and of treating psychological distress following surgery on the eye, the method comprising administering a cyclosporin composition to the affected eye of an individual. | 01-13-2011 |
| 20110009340 | COMBINATION OF AN IRON CHELATOR AND AN IMMUNOSUPPRESSANT AND USE THEREOF - The invention relates to a combination comprising an iron chelator and an immunosuppressant, to the use of such combination for the improvement of immunosuppression, e.g. in hematopoietic stem cell transplantation. | 01-13-2011 |
| 20110021443 | OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES - Oil-in-water emulsion including a non-steroidal anti-inflammatory drug and a quaternary ammonium halide useful for the prevention and treatment of inflammation in the eye, and process for manufacturing thereof. | 01-27-2011 |
| 20110028405 | SULFAMIDES AS ZAP-70 INHIBITORS - The invention relates to compounds of formula (I) | 02-03-2011 |
| 20110028406 | Pharmaceutical Compositions Comprising A Cyclosporin, A Hydrophilic Surfactant and a Lipophilic Surfactant - Pharmaceutical compositions, which enable high absorption when administered orally, and which comprise a cyclosporin or cyclosporin derivative dissolved in a solvent-surfactant system further comprising a hydrophilic surfactant and a lipophilic surfactant, with minimal quantities of solvents. | 02-03-2011 |
| 20110039790 | ENHANCED OCULAR NEUROPROTECTION AND NEUROSTIMULATION - Use of topically applied cyclosporine to enhance corneal sensitivity restoration rate in an eye of an individual after ocular surgery such as laser-assisted in situ keratomileusis (LASIK) in which nerves are severed. | 02-17-2011 |
| 20110065651 | HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY - The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: | 03-17-2011 |
| 20110071090 | Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle - A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously. | 03-24-2011 |
| 20110082091 | Method for Preclinical Testing of Immunomodulatory Drugs - The invention teaches a method for testing a prospective or known immunomodulatory drug for T-cell activation, comprising the step of contacting in-vitro a peripheral blood mononuclear cell (PBMC) culture with a predetermined amount of the prospective or known immunomodulatory drug and observing the PBMC culture for T-cell activation using a readout system, upon contact with the prospective or known immunomodulatory drug, wherein the cell density of a PBMC preculture is adjusted such that cell-cell contact of the PBMC is enabled and wherein the PBMC preculture is cultured for at least 12 h. | 04-07-2011 |
| 20110092443 | CYCLOSPORINE COMPOSITIONS FOR ENHANCING NAIL GROWTH - The present invention is directed to cyclosporine compositions and methods for stimulating the growth of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to increase nail growth and thicken, strengthen and smooth the nail. The composition is also effective in strengthening and growing nails, including fingernails and toenails. | 04-21-2011 |
| 20110098236 | DIAMIDE INHIBITORS OF CYTOCHROME P450 - Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes. | 04-28-2011 |
| 20110098237 | METHODS FOR INHIBITING DRUG DEGRADATION - Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes. | 04-28-2011 |
| 20110124575 | METHOD FOR PROCESSING MICROBIOLOGICALLY PRODUCED CYCLIC OLIGOPEPTIDES - The present invention relates to a method for processing microbiologically produced, non-polar, cyclic oligopeptides comprising the step of a) extracting the entire fermentation broth incident to the microbiological production process using a liquid extractant that contains ether and is immiscible with water, wherein the amount of extractant is sufficient to form a two-phase system together with the total fermentation broth, and novel solvates of cyclosporin A and methyl-t-butyl ether. | 05-26-2011 |
| 20110136744 | CYCLOSPORIN ANALOG FORMULATIONS - The present disclosure relates to formulations containing cyclosporin analogs that are structurally similar to cyclosporin A, in particular isomeric mixtures of cyclosporin analogs that are structurally similar to cyclosporin A. The formulations form stable microemulsion preconcentrates and may provide superior drug bioavailability and/or may reduce one or more adverse effects associated with the administration of cyclosporin. Also disclosed are methods for using and preparing the formulations. | 06-09-2011 |
| 20110152201 | EMULSION PRECONCENTRATES CONTAINING CYCLOSPORIN OR A MACROLIDE - This invention provides an emulsion, e.g., microemulsion, pre-concentrate comprising a difficultly soluble active agent and a carrier medium. The active agent may, e.g., be a cyclosporin or a macrolide. | 06-23-2011 |
| 20110166080 | DEUTERATED CYCLOSPORINE ANALOGS AND METHODS OF MAKING THE SAME - Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporin and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution of amino acid 1; and (2) deuterium substitution at key sites of metabolism of the cyclosporine A molecule such as amino acids 1, 4, 9. Also disclosed are methods of producing the cyclosporine derivatives and method of producing immunosuppression with reduced toxicity with the disclosed cyclosporine derivatives. | 07-07-2011 |
| 20110294744 | CYCLOSPORIN EMULSIONS - Disclosed herein is a composition comprising cyclosporin A at a concentration between about 0.001% (w/v) and about 1.0% (w/v), a plant oil at a concentration between about 0.01% (w/v) and about 10% (w/v), and macrogol 15 hydroxystearate at a concentration between about 0.01% (w/v) and about 10% (w/v). | 12-01-2011 |
| 20110306564 | SOLID COMPOSITION, MICROPARTICLES, MICROPARTICLE DISPERSION LIQUID, AND MANUFACTURING METHODS FOR THESE - In a dissolving step, in a container | 12-15-2011 |
| 20120022001 | METHOD OF MITIGATING ADVERSE DRUG EVENTS USING OMEGA-3 FATTY ACIDS AS A PARENTERAL THERAPEUTIC DRUG VEHICLE - A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously. | 01-26-2012 |
| 20120028910 | STORAGE-STABLE AQUEOUS OPHTHALMIC FORMULATIONS - Storage-stable, topically ocularly administrable aqueous ophthalmic formulations containing at least one closporine are useful for treating and/or preventing ophthalmic diseases or disorders afflicting humans or animals, notably related to inflammatory conditions, more particularly administrable to the front of the eye and which provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision. | 02-02-2012 |
| 20120077756 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF OPHTHALMIC DISORDERS - The invention features methods, kits, and compositions for the treatment of ophthalmic disorders. The compositions include a corticosteroid in combination with a non-steroidal immunophilin-dependent immunosuppressant. | 03-29-2012 |
| 20120094932 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: | 04-19-2012 |
| 20120129789 | COMPOSITIONS AND METHODS FOR HAIR GROWTH - The present invention is directed to compositions and methods comprising the use of bimatoprost and cyclosporine, used concurrently and in combination, to grow hair and for the treatment of all types of hair loss conditions such as but not limited to alopecia areata. The present invention is also directed to compositions containing bimatoprost and cyclosporine A to grow hair on the scalp and other areas of the body and methods of administration of the compositions. | 05-24-2012 |
| 20120135939 | Cyclosporin Analogs - Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions. | 05-31-2012 |
| 20120135940 | PHARMACEUTICAL COMPOSITIONS FOR LIPOPHILIC DRUGS - Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C | 05-31-2012 |
| 20120184496 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS - Described herein are ophthalmic pharmaceutical compositions, wherein the ophthalmic pharmaceutical compositions are in a form suitable for administration to an eye of a mammal. Ophthalmic pharmaceutical compositions disclosed herein include at least one DP | 07-19-2012 |
| 20120214745 | Deuterated Cyclosporine Analogs and Methods of Making the Same - Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporin and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution of amino acid 1; and (2) deuterium substitution at key sites of metabolism of the cyclosporine A molecule such as amino acids 1, 4, 9. Also disclosed are methods of producing the cyclosporine derivatives and method of producing immunosuppression with reduced toxicity with the disclosed cyclosporine derivatives. | 08-23-2012 |
| 20120225826 | Transporters Comprising Spaced Arginine Moieties - The present invention provides compositions and methods for enhancing transport of biologically active compounds across biological membranes and across and into animal epithelial or endothelial tissues. The composition includes a biologically active agent and a transport moiety. The transport moiety includes a structure selected from the group consisting of (ZYZ) | 09-06-2012 |
| 20120225827 | SILICONE-BASED OPHTHALMIC FORMULATIONS - Compositions, products and methods including silicone based excipients are provided. The compositions, products and methods of the present invention are particularly useful for the treatment of ophthalmic diseases. | 09-06-2012 |
| 20120232018 | POLYCARBONATES FOR DELIVERY OF DRUGS AND METHODS OF PREPARATION THEREOF - A cyclic carbonate monomer has the formula (2): | 09-13-2012 |
| 20120252740 | HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME - Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed. | 10-04-2012 |
| 20120264698 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING AUTOIMMUNE CONDITIONS AND DELAYING OR PREVENTING AUTOIMMUNE RELATED PATHOLOGIC PROGRESSIONS - Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases. | 10-18-2012 |
| 20120270804 | METHODS FOR THE TREATMENT AND PREVENTION OF OCULAR DISORDERS - Provided herein are methods for treatment of ocular diseases. The methods comprise administering a compound of general Formula (I): wherein R | 10-25-2012 |
| 20120270805 | CYCLOSPORIN COMPOSITIONS - A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols, ethoxylated alkylphenols, ethoxylated aryl phenols, ethoxylated fatty acids, ethoxylated fatty acids, ethoxylated fatty esters and oils, fatty alcohols, fatty esters, glycol esters, lanolin-based derivatives, lecithin and lecithin derivatives, lignin and lignin derivatives, methyl esters, monoglycerides and derivatives, phosphalipids, polyacrylic acids, polyethylene glycols, polyethylene oxide-polypropylene oxide copolymers, polyethylene oxides, polymeric surfactants, polypropylene oxides, propoxylated alcohols, propoxylated alkyl phenols, propoxylated fatty acids, protein-based surfactants, sarcosine derivatives, silicone-based surfactants, sorbitan derivatives, stearates, sucrose and glucose esters and derivatives, and combinations thereof. | 10-25-2012 |
| 20120289470 | TRANSMUCOSAL ADMINISTRATION OF DRUG COMPOSITIONS FOR TREATING AND PREVENTING DISORDERS IN ANIMALS - The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier. | 11-15-2012 |
| 20120289471 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX - The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same. | 11-15-2012 |
| 20120322746 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF OPHTHALMIC DISORDERS - The invention features methods, kits, and compositions for the treatment of ophthalmic disorders. The compositions include a corticosteroid in combination with a non-steroidal immunophilin-dependent immunosuppressant. | 12-20-2012 |
| 20130005665 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS - Provided herein are compositions, which include an active pharmaceutical ingredient and macrogol 15 hydroxystearate, and methods for using the same for treating diseases or disorder. | 01-03-2013 |
| 20130023482 | CRYSTALLINE FORM OF CYCLOSPORINE A, METHODS OF PREPARATION, AND METHODS FOR USE THEREOF - The present invention relates generally to crystalline forms of cyclosporine A and particularly to a newly identified form of cyclosporine A. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders. | 01-24-2013 |
| 20130029919 | TWO PART FORMULATION SYSTEM FOR OPTHALMIC DELIVERY - Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent. | 01-31-2013 |
| 20130040895 | Pharmaceutical Formulations and Methods for Treating Ocular Conditions - Biodegradable drug delivery systems suitable for injection into an ocular region or site and methods for treating ocular conditions. The drug delivery systems provide increased drug residency time and attendant therapeutic benefit. | 02-14-2013 |
| 20130059795 | Novel Composition Of Matter For Delivering Lipid-Soluble Materials, And A Method For Producing It - This invention describes a novel composition of matter describing a complex comprising leaf protein and a lipophilic substance(s), along with the method of producing it. Delivery of lipid-soluble materials into the body is challenging because they are generally highly insoluble in water and very subject to oxidative degradation. The inventors have found that leaf protein—the water-soluble proteins derived from plant leaves—can efficiently form a complex with lipophilic materials. This leaf protein—lipid-soluble material complex is an effective carrier of lipophilic substances. As such, the leaf protein—lipid-soluble material complex disclosed herein can be used for the delivery of lipophilic vitamins, fatty acids, caretenoids, lipophilic drugs, and other lipophilic materials. This complex can be used to deliver lipophiles in foods, nutritional and dietary supplements, topical compositions and in pharmaceutical products. | 03-07-2013 |
| 20130059796 | CYCLOSPORIN COMPOSITIONS - Cyclosporin A compositions are disclosed herein comprising an oil and a surfactant. These are useful in the treatment of dry eye disease. | 03-07-2013 |
| 20130096069 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO OCULAR TISSUES - This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length. | 04-18-2013 |
| 20130109630 | METHODS FOR DIAGNOSING AND ASSESSING RISK OF DEVELOPING GLOMERULOSCLEROSIS | 05-02-2013 |
| 20130123193 | CYCLOSPORIN A FORM 2 AND METHOD OF MAKING SAME - Disclosed herein are methods of making cyclosporin A Form 2. | 05-16-2013 |
| 20130123194 | AUTOCLAVABLE SUSPENSIONS OF CYCLOSPORIN A FORM 2 - Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations. | 05-16-2013 |
| 20130123195 | SUSTAINED ACTION FORMULATION OF CYCLOSPORIN FORM 2 - Disclosed herein are methods of treating diseases of the eye by administering to the subconjunctival space a formulation comprising cyclosporin A form 2 and a hydrogel. | 05-16-2013 |
| 20130150311 | MIXED POLOXAMER EXCIPIENTS - In one aspect, the present invention is directed to a dry, flowable and compressible composition, useful as a pharmaceutical excipient, which composition comprises a mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers, and which possesses a Carr index of less than about 20. In other aspects, the present invention is directed a pharmaceutical composition comprising such adjuvant and a pharmaceutically active ingredient; as well as to a method of making the compositions. | 06-13-2013 |
| 20130172268 | DRUG DELIVERY THROUGH HYDROGEL PLUGS - An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel absorbing physiological water to swell to at least 1 mm in cross-sectional width and conformably fit a canaliculus, with the hydrogel comprising a therapeutic agent dispersed through the hydrogel for release to an eye, with the hydrogel having a water content of at least about 50% by weight or volume when allowed to fully hydrate in vitro in physiological saline. | 07-04-2013 |
| 20130190252 | PHARMACEUTICAL FORMULATION CONTAINING LIPOPHILIC DRUGS AND MILK AS A SOLUBILIZING/DISPENSING AGENT AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to an improved pharmaceutical composition and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of a lipophilic active ingredient with milk as a solubilizing/dispersing agent and methods for the preparation thereof. | 07-25-2013 |
| 20130244952 | COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS - The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell. | 09-19-2013 |
| 20130267472 | AQUEOUS OPHTHALMIC SOLUTION BASED ON CYCLOSPORIN - This invention concerns an aqueous ophthalmic solution containing an immunosuppressive agent, such as cyclosporin A, and at least three polymers. The three polymers are preferably a combination of a cellulose derivative, a polyvinyl derivative, and a macrogolglycerol hydroxystearate. | 10-10-2013 |
| 20130303462 | USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME - The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome. | 11-14-2013 |
| 20130316961 | TREATMENT OF MECP-2 ASSOCIATED DISORDERS - The invention relates to the use of cystamine, cysteamine, or a salt thereof, or of calcineurin inhibitors for treating a MeCP2-associated disorder such as Rett syndrome. | 11-28-2013 |
| 20130324480 | CYCLOSPORIN A ANALOGS - The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye. | 12-05-2013 |
| 20130324481 | SUSTAINED RELEASE EYE DROP FORMULATIONS - This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably α-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents. | 12-05-2013 |
| 20130331336 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS - Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8. | 12-12-2013 |
| 20130331337 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS - Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8. | 12-12-2013 |
| 20130331338 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS - Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8. | 12-12-2013 |
| 20130331339 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS - Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8. | 12-12-2013 |
| 20130331340 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS - Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8. | 12-12-2013 |
| 20130331341 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS - Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8. | 12-12-2013 |
| 20130338082 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS - Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8. | 12-19-2013 |
| 20130338083 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS - Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8. | 12-19-2013 |
| 20130345147 | PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN - Therapeutic methods are disclosed herein. | 12-26-2013 |
| 20130345148 | PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN - Therapeutic methods are disclosed herein. | 12-26-2013 |
| 20130345149 | SILICONE-BASED OPHTHALMIC FORMULATIONS - Compositions, products and methods including silicone based excipients are provided. The compositions, products and methods of the present invention are particularly useful for the treatment of ophthalmic diseases. | 12-26-2013 |
| 20130345150 | OPHTHALMIC COMPOSITION - An ophthalmic composition comprising a polyaphron dispersion. | 12-26-2013 |
| 20140005123 | PHARMACEUTICAL COMPOSITIONS | 01-02-2014 |
| 20140005124 | CYCLOSPORIN DERIVATIVES FOR TREATING INFLAMMATORY DISEASES AND CONDITIONS | 01-02-2014 |
| 20140011750 | PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN - Therapeutic methods are disclosed herein. | 01-09-2014 |
| 20140011751 | PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN - Therapeutic methods are disclosed herein. | 01-09-2014 |
| 20140031298 | Compositions and Methods for Localized Therapy of the Eye - Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers. | 01-30-2014 |
| 20140038904 | PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN - Therapeutic methods are disclosed herein. | 02-06-2014 |
| 20140038905 | PREVENTION AND TREATMENT OF OCULAR SIDE EFFECTS WITH A CYCLOSPORIN - Therapeutic methods are disclosed herein. | 02-06-2014 |
| 20140045772 | CYCLOSPORIN COMPOSITIONS - A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols, ethoxylated alkylphenols, ethoxylated aryl phenols, ethoxylated fatty acids, ethoxylated fatty acids, ethoxylated fatty esters and oils, fatty alcohols, fatty esters, glycol esters, lanolin-based derivatives, lecithin and lecithin derivatives, lignin and lignin derivatives, methyl esters, monoglycerides and derivatives, phosphalipids, polyacrylic acids, polyethylene glycols, polyethylene oxide-polypropylene oxide copolymers, polyethylene oxides, polymeric surfactants, polypropylene oxides, propoxylated alcohols, propoxylated alkyl phenols, propoxylated fatty acids, protein-based surfactants, sarcosine derivatives, silicone-based surfactants, sorbitan derivatives, stearates, sucrose and glucose esters and derivatives, and combinations thereof. | 02-13-2014 |
| 20140057854 | TOPICAL FORMULATIONS AND USES THEREOF - Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions. | 02-27-2014 |
| 20140057855 | CYCLOSPORIN COMPOSITIONS - A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein. | 02-27-2014 |
| 20140094418 | PALATABLE DUCTILE CHEWABLE VETERINARY COMPOSITION - The present invention is directed to palatable ductile chewable veterinary composition for oral administration. The composition is capable of killing endo-parasites and ecto-parasites and/or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any warm-blooded non-human animal, including herd animals, like horses, cattle, sheep or poultry and preferably pets like dogs and cats. It consists basically of (A) an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener; and (E) up to 9% water. | 04-03-2014 |
| 20140107040 | SUBSTITUTED N-ARYL PYRIDINONES - Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 04-17-2014 |
| 20140128329 | OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPROLACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS - Compositions and methods related to ophthalmic use of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein. | 05-08-2014 |
| 20140179620 | GENE EXPRESSION MARKERS FOR INFLAMMATORY BOWEL DISEASE - The present invention relates to methods of gene expression profiling for inflammatory bowel disease pathogenesis, in which the differential expression in a test sample from a mammalian subject of one or more IBD markers relative to a control is determined, wherein the differential expression in the test sample is indicative of an IBD in the mammalian subject from which the test sample was obtained. | 06-26-2014 |
| 20140187497 | Ocular Drug Delivery Devices - A method of forming an ocular delivery device includes exposing a solid, shaped cellulose polymer to a solution including an active pharmaceutical ingredient (API) and a solvent capable of solubilizing the API, wherein the polymer absorbs at least a portion of the solution, including the API and solvent. The method may further include removing at least a portion of the absorbed solvent from the polymer by allowing the absorbed solvent to evaporate from the polymer or by drying the polymer. A variety of cellulose polymers may be used, including hydroxypropyl cellulose. A variety of APIs may be used, including Cyclosporine, Tobramycin and Vancomycin. Ocular delivery devices prepared by the methods may be used to treat a variety of eye disorders. | 07-03-2014 |
| 20140206625 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING AUTOIMMUNE CONDITIONS AND DELAYING OR PREVENTING AUTOIMMUNE RELATED PATHOLOGIC PROGRESSIONS - Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases. | 07-24-2014 |
| 20140206626 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS - Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin exponent to the hydrophobic component is less than 0.8. | 07-24-2014 |
| 20140213532 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES - This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidine or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length. | 07-31-2014 |
| 20140213533 | METHODS TO DETECT, TREAT AND PREVENT ACUTE CELLULAR REJECTION IN KIDNEY ALLOGRAFTS - Methods for prevention and treatment of kidney transplant rejection are described that involve determination, analysis and computation of a 3-gene molecular signature of levels of specific RNAs (IP-10 mRNA, CD3ε mRNA, and 18S rRNA) in urinary sample cells. The methods and devices described herein are diagnostic and prognostic of acute cellular rejection in kidney allografts. | 07-31-2014 |
| 20140235552 | INSULIN INDEPENDENCE AMONG PATIENTS WITH DIABETES UTILIZING A PPI IN COMBINATION WITH AN IMMUNE TOLERANCE AGENT - To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life. Compositions and methods are provided for insulin-independence among type 2 patients using PPIs when combined with therapeutic agents utilized for the treatment of type 2 diabetes. | 08-21-2014 |
| 20140249092 | CYCLOSPORIN ANALOG FORMULATIONS - The present disclosure relates to formulations containing cyclosporin analogs that are structurally similar to cyclosporin A, in particular isomeric mixtures of cyclosporin analogs that are structurally similar to cyclosporin A. The formulations form stable microemulsion preconcentrates and may provide superior drug bioavailability and/or may reduce one or more adverse effects associated with the administration of cyclosporin. Also disclosed are methods for using and preparing the formulations. | 09-04-2014 |
| 20140256651 | Cyclosporine A steroid conjugates - The present invention describes Cyclosporine A/steroid hybrid analogs. These single drug entities are formed by connecting a steroid with Cyclosporine A. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. | 09-11-2014 |
| 20140296158 | SUSTAINED ACTION FORMULATION OF CYCLOSPORIN FORM 2 - Disclosed herein are methods of treating diseases of the eye by administering to the subconjunctival space a formulation comprising cyclosporin A form 2 and a hydrogel. | 10-02-2014 |
| 20140303091 | OCULAR FORMULATIONS OF NORKETOTIFEN - Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen. | 10-09-2014 |
| 20140303092 | HEXADECYLOXYPROPYL CIDOFOVIR FOR THE TREATMENT OF DOUBLE-STRANDED DNA VIRUS INFECTION - The present application provides methods and compositions for treatment or prevention of dsDNA virus infection in post-hematopoietic cell transplant (HCT or HSCT) patients. | 10-09-2014 |
| 20140315827 | CRYSTALLINE FORM OF CYCLOSPORINE A, METHODS OF PREPARATION, AND METHODS FOR USE THEREOF - The present invention relates generally to crystalline forms of cyclosporine A and particularly to a newly identified form of cyclosporine A. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders. | 10-23-2014 |
| 20140323412 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE - Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof. | 10-30-2014 |
| 20140378391 | Ophthalmic Lipophilic Drug Delivery Vehicle Formulations - The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation. | 12-25-2014 |
| 20150011480 | METHOD OF TREATING BLURRED VISION AND OTHER CONDITIONS OF THE EYE WITH CYCLOSPORIN COMPOSITIONS - Disclosed herein is a method of treating blurred vision, of increasing keratocyte density, of increasing goblet cell density, and of treating psychological distress following surgery on the eye, the method comprising administering a cyclosporin composition to the affected eye of an individual. | 01-08-2015 |
| 20150025020 | SELF-PRESERVED OIL DISPERSIONS COMPRISING BORIC ACID - The present invention relates to a self-preserved oil dispersion. Especially, the present invention relates to a self-preserved oil dispersion including a dispersed oil phase, an aqueous phase and at least one surfactant, wherein said oil dispersion comprises boric acid in an amount ranging from 0.005% to 0.075% in weight of the total weight of the oil dispersion, said amount of boric acid being a preservative effective amount so that the oil dispersion has a preservative activity. | 01-22-2015 |
| 20150031628 | METHODS AND FORMULATIONS FOR CONVERTING INTRAVENOUS AND INJECTABLE DRUGS INTO ORAL DOSAGE FORMS - Oral dosage compositions for drugs normally given intravenously such as Paclitaxel, containing a plant sterol to enhance solubility and a small intestine efflux inhibitor to prevent P-glycoprotein from being a barrier to absorption. | 01-29-2015 |
| 20150038431 | INFLAMMATORY EYE DISORDERS - Provided herein are methods of evaluating efficacy of a treatment in a subject having eye inflammation (e.g., a subject having dry eye syndrome) and selecting a subject for participation in a clinical study. Also provided are methods of treating a subject having eye inflammation (e.g., a subject having dry eye syndrome). | 02-05-2015 |
| 20150045309 | CYCLOSPORIN EMULSIONS - Disclosed herein is a composition comprising cyclosporin A at a concentration between about 0.001% (w/v) and about 1.0% (w/v), a plant oil at a concentration between about 0.01% (w/v) and about 10% (w/v), and macrogol 15 hydroxystearate at a concentration between about 0.01% (w/v) and about 10% (w/v). | 02-12-2015 |
| 20150057233 | CALCINEURIN INHIBITORS FOR USE IN THE TREATMENT OF LESIONAL VESTIBULAR DISORDERS - The present invention relates to a calcineurin inhibitor for use in the treatment of a lesional vestibular disorder. | 02-26-2015 |
| 20150072938 | CATIONIC GRAFT-COPOLYMER FOR DRUG DELIVERY SYSTEM - A cationic graft-copolymer for a drug delivery system comprising a unit derived from a having a hydroxyl groups, namely, a cationic polysaccharide of the following formula (1) (C | 03-12-2015 |
| 20150111833 | Method Of Treating An Ocular Disease And Compositions Effective For Treating An Ocular Disease - Methods and compositions are provided for treating an ocular disease in a subject in need thereof by increasing the bioavailability of a drug in the subjects eye. By one approach, the ocular disease is endophthalmitis. The methods and compositions provided herein include an efflux transporter inhibitor and a drug effective for treating the ocular disease. The efflux transporter inhibitor is effective to reduce the efflux of the drug through at least one of Pglycoprotein (Pgp), breast cancer resistant protein (BCRP), and multidrug resistant associated protein 19 (MRP19). In one aspect, cyclosporine A is the efflux transporter inhibitor. | 04-23-2015 |
| 20150133390 | Identification of New Therapeutic Uses for Known Therapeutic Agents - Methods for identifying new therapeutic activities for known therapeutic agents, as well as systems for practicing the same, are provided. Aspects of the invention further include are methods and compositions for the treatment of an acute graft rejection (AR). | 05-14-2015 |
| 20150133391 | CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS THEREOF - Methods, devices, compositions and kits are provided for analysis of the microbiome or individual components thereof in an individual. The methods find use in a determination of infection, in analysis of the microbiome structure, in determining the immunocompetence of an individual, and the like. In some embodiments of the invention, the individual is treated with a therapeutic regimen, e.g. drugs, diet, radiation therapy, and the like. | 05-14-2015 |
| 20150148299 | TOPICAL FORMULATIONS AND USES THEREOF - Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions. | 05-28-2015 |
| 20150313854 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE - The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist. | 11-05-2015 |
| 20150313959 | NOVEL PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF PERIODONTAL DISEASE - The present invention relates to novel treatments of periodontal disease by administering a suitable formulation of a cyclophilin inhibitor. The present invention further relates to novel pharmaceutical compositions containing said cyclophilin inhibitor compounds. | 11-05-2015 |
| 20150343017 | CYCLOSPORIN COMPOSITIONS - A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols, ethoxylated alkylphenols, ethoxylated aryl phenols, ethoxylated fatty acids, ethoxylated fatty acids, ethoxylated fatty esters and oils, fatty alcohols, fatty esters, glycol esters, lanolin-based derivatives, lecithin and lecithin derivatives, lignin and lignin derivatives, methyl esters, monoglycerides and derivatives, phosphalipids, polyacrylic acids, polyethylene glycols, polyethylene oxide-polypropylene oxide copolymers, polyethylene oxides, polymeric surfactants, polypropylene oxides, propoxylated alcohols, propoxylated alkyl phenols, propoxylated fatty acids, protein-based surfactants, sarcosine derivatives, silicone-based surfactants, sorbitan derivatives, stearates, sucrose and glucose esters and derivatives, and combinations thereof. | 12-03-2015 |
| 20150352089 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: | 12-10-2015 |
| 20150366799 | METHOD OF TREATING ALLERGIC CONJUNCTIVITIS WITH CYCLOSPORIN COMPOSITIONS - Disclosed herein is a method of treating allergic conjunctivitis, the method comprising the step of topically administering to an eye affected with such a condition a composition comprising cyclosporin, at a concentration between about 0.001% (w/v) to about 0.01% (w/v). | 12-24-2015 |
| 20160022765 | Cyclosporin Analogs - Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions. | 01-28-2016 |
| 20160039880 | CYCLOSPORIN A ANALOGS - The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye. | 02-11-2016 |
| 20160045617 | TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY - The present invention provides, inter alia, methods and pharmaceutical compositions for treating or ameliorating an effect of proximal spinal muscular atrophy (SMA) and methods for preventing or slowing motor neuron death in a subject having SMA. The methods include administering to a subject in need thereof a modulator of a gene selected from the group consisting of phosphodiesterase 1c (Pde1c), Calbindin 2 (Calb2), Egl nine homolog 3 (Eg13), Metabotropic glutamate receptor 8 (mGluR8), Syn aptotagmin 1 (Syt1), CUGBP, Elav-like family member 4 (Celf4), and combinations thereof in an amount effective to treat or ameliorate an effect of SMA. Also provided are methods for preventing or slowing motor neuron death. | 02-18-2016 |
| 20160095839 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING AUTOIMMUNE CONDITIONS AND DELAYING OR PREVENTING AUTOIMMUNE RELATED PATHOLOGIC PROGRESSIONS - Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases. | 04-07-2016 |
| 20160143988 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS - Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8. | 05-26-2016 |
| 20160151496 | SUSTAINED RELEASE EYE DROP FORMULATIONS | 06-02-2016 |
| 20160175316 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | 06-23-2016 |
| 20160193286 | Treatment of Rhinosinusitis with P-glycoprotein Inhibitors | 07-07-2016 |
| 20170231908 | AMPHIPHILIC BLOCK COPOLYMERS FOR DELIVERY OF ACTIVE AGENTS | 08-17-2017 |
| 20100298208 | BIOFILM PREVENTION USING LACTOFERRIN - This invention relates to methods and compositions capable of inhibiting biofilm formation. Specifically, provided herein are methods and compositions using Lactoferrin for the inhibition of biofilm formation. | 11-25-2010 |
| 20110009313 | POLYETHYLENE GLYCOLATED LACTOFERRIN COMPLEX AND METHOD OF PRODUCING THE SAME - A method of producing a polyethylene glycolated (PEGylated) lactoferrin complex having a linear polyethylene glycol (PEG) or a modified product thereof covalently bonded to lactoferrin via an amide bond includes causing a reaction to occur in a reaction liquid, which contains the lactoferrin and a linear PEG derivative having a para-nitrophenol leaving group, under conditions that allow formation of an amide group between the PEG derivative and the lactoferrin. A PEGylated lactoferrin complex contains a linear PEG or a modified product thereof covalently bonded to lactoferrin via an amide bond, and a pharmaceutical composition includes a PEGlyated lactoferrin complex, a therapeutically inert base, and/or an additive. | 01-13-2011 |
| 20110301077 | METHOD FOR PRODUCTION OF LACTOFERRIN - The invention concerns a method for production of lactoferrin comprising at least the steps of: a) disposing of raw material that have not been treated at a temperature greater than 500 C, b) submitting this raw material to a treatment in order to obtain a solution of Lactenin (LN) or Milk Basic Protein (MBP), c) submitting this LN or MBP solution to a step of purification on a cation exchange resin equilibrated with an acetate buffer at a pH between 4 and 9 and eluted with different buffer solutions containing different solute concentrations, d) and collecting a fraction containing Lactoferrin having more than 95% of purity, having no polymers and substantially free of LPS, endotoxins and angiogenin. It also concerns the Lactoferrin obtained having more than 95% of purity, substantially free of LPS, endotoxins and angiogenin with an iron saturation level comprised between 9% to 15%. | 12-08-2011 |
| 20120122767 | LACTOFERRIN-BASED BIOMATERIALS FOR TISSUE REGENERATION AND DRUG DELIVERY - The invention provides biomatrix compositions comprising cross-linked lactoferrin, either alone or in combination with other organic or inorganic components. Also provided are methods of making and using the biomatrix compositions. As described herein, cross-linked lactoferrin biomatrix retains the bioactivities of the lactoferrin molecule. The biomatrix composition can act as a matrix for cell adhesion and growth and is particularly useful in musculoskeletal tissue regeneration. The biomatrix compositions can be pre-formed or injectable and can act as a cell, drug or protein delivery vehicle. | 05-17-2012 |
| 20120142583 | Methods of inhibiting and treating bacterial biofilms by metal chelators - The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron stimulates surface motility in bacteria thus inhibiting the ability of a bacterial population to develop into a biofilm. | 06-07-2012 |
| 20120172288 | USE OF NUTRITIONAL COMPOSITIONS INCLUDING LACTOFERRIN IN SUPPORTING RESISTANCE TO DISEASES AND CONDITIONS - The present disclosure relates to the use of nutritional compositions including lactoferrin produced by a non-human source in supporting resistance to diseases or conditions caused by bacterial and viral pathogens. | 07-05-2012 |
| 20120184483 | LACTOFERRIN AND NEURONAL HEALTH AND DEVELOPMENT IN THE INFANT GUT - The present invention relates generally to the field of neuronal health, neuronal protection and neuronal development. One embodiment of the present invention relates to a composition that can be used for the treatment or prevention of a delayed development of the enteric nervous system. Neuronal cells in the gut can be protected. Disorders linked to a delayed development of the enteric nervous system and/or to an impaired enteric nervous system can be treated or prevented by the administration of lactoferhn containing compositions. | 07-19-2012 |
| 20120184484 | LACTOFERRIN AND BRAIN HEALTH AND DEVELOPMENT IN INFANTS - The present invention relates generally to the field of brain development and brain health. One embodiment of the present invention relates to a composition that can be used for the treatment or prevention of a delayed brain development and/or a delayed development of the nervous system. Also cognitive performance can be increased. | 07-19-2012 |
| 20120245080 | MINERAL SALT-SULFONIC ACID COMPOSITIONS AND METHODS OF USE - The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions. | 09-27-2012 |
| 20130210708 | METHODS OF INHIBITING AND TREATING BACTERIAL BIOFILMS BY METAL CHELATORS - The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron stimulates surface motility in bacteria thus inhibiting the ability of a bacterial population to develop into a biofilm. | 08-15-2013 |
| 20130310306 | HUMAN LACTOFERRIN DERIVED PEPTIDES AND THEIR USE - The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations, pain, wounds, scar and/or tumours. | 11-21-2013 |
| 20140357550 | Pharmaceutical Composition for Treatment of Acute Toxic Conditions - A pharmaceutical composition for treatment of acute toxic conditions relates to the field of medicine, particularly to nanotechnology and toxicology, and can be used for prophylaxis and therapy of various etiologies of toxic states, including the acute ones. The claimed pharmaceutical composition for treatment of acute toxic conditions contains protein—the human lactoferrin—and further comprises of non-replicating nanoparticles with inset of human lactoferrin gene and formulating buffer. The dose of the claimed pharmaceutical composition is 3 ml. The dose of the claimed pharmaceutical composition comprises: human lactoferrin—from 50 to 100 mg; non-replicating nanoparticles—7×10 | 12-04-2014 |
| 20150087582 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORAL DISEASES - Compositions comprising iron-sequestering glycoproteins, chelating agents, stabilizing agents, binding agents, surfactants, fluorides, antimicrobials and a pH adjuster or buffer for the prevention and treatment of oral cavity diseases caused by dental plaque/biofilm, such as dental caries, gingivitis and periodontitis, through anti-infective properties are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive oral bacteria occurring in polymicrobial dental biofilms. The composition may be in the form of wash, rinse, soak, paste, gel, spray, or other suitable form. Additionally, the invention offers an efficient method of delivering the formulated composition containing a PEGylated or fluorinated iron-sequestering glycoprotein and one or two chelating agents or chelating agents alone using either a liposomal or a nanoparticle delivery system. | 03-26-2015 |
| 20150320839 | COMPOSITION FOR TOPICAL USE COMPRISING LACTOFERRIN - The present invention relates to a composition comprising lactoferrin and to its use in the prevention of preterm delivery. | 11-12-2015 |
